Plain-English translation of NCT06534762 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a medication called Milaberon combined with standard cancer treatments for people with advanced solid tumors that cannot be operated on. The study includes several types of cancer—lung cancer, colorectal cancer, pancreatic cancer, triple-negative breast cancer, lymphoma, and head and neck cancer. Researchers want to see whether adding this new oral medication to existing chemotherapy or immunotherapy treatments can help fight these cancers more effectively.
Current treatments for advanced cancers help many patients, but doctors are always looking for ways to improve outcomes. This medication may work in a new way that could enhance how well standard treatments work, potentially giving patients better chances of response.
You likely qualify if…
You likely don't qualify if…
You would take the new medication (Milaberon) as a 100 mg tablet by mouth once daily in the morning, along with your standard cancer treatment (which could be chemotherapy, immunotherapy, or a combination depending on your cancer type). You would continue this treatment until your cancer progresses or until side effects become too severe. Throughout the study, you would have regular clinic visits for blood tests and imaging scans to monitor how you are responding to treatment. If you experience serious side effects, your dose may be lowered or paused until side effects improve.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China